2016 Walk Photos
2017 SOS Walk has been Postponed.
New Activities are being planned for the September Walk Date.
Learn more in the letter below and stay tuned to our website.
The U.S. Food and Drug Administration has approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.
"Endari is the first treatment approved for patients with sickle cell disease in almost 20 years," said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence. "Until now, only one other drug was approved for patients living with this serious, debilitating condition."
To learn more, click here!
FDA Approves New Treatment for Sickle Cell Disease